The company has claimed that 91.15% of covid 19 patients treated with virafin were RTPCR negative by day 7
A Thread on "Virafin"
1/n
A Thread on "Virafin"
1/n
What Virafin is composed of?
As per Zydus Cadila its drug ‘Virafin’ is used for treating moderate cases of COVID-19 in adults. It is chemically Pegylated Interferon Alpha-2b. It ’showed clinical and virological improvement in moderate COVID-19 cases.
2/n
As per Zydus Cadila its drug ‘Virafin’ is used for treating moderate cases of COVID-19 in adults. It is chemically Pegylated Interferon Alpha-2b. It ’showed clinical and virological improvement in moderate COVID-19 cases.
2/n
For what it was originally approved?
The drug was originally approved for liver disease Hepatitis C and launched in India 10 years ago. For hepatitis C it is typically used with ribavirin and cure rates are between 33 and 82%. It is being repurposed to treat COVID-19.
3/n
The drug was originally approved for liver disease Hepatitis C and launched in India 10 years ago. For hepatitis C it is typically used with ribavirin and cure rates are between 33 and 82%. It is being repurposed to treat COVID-19.
3/n
Claims being made?
The pharma company said that the treatment reduces hours of supplemental oxygen in patients,help patients recover faster and avoid many complications.
4/n
The pharma company said that the treatment reduces hours of supplemental oxygen in patients,help patients recover faster and avoid many complications.
4/n
Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19:
A phase II, randomized, controlled, open-label study
Concludes that significant improvement in clinical status on day 15 is likely due to faster viral reduction compared to SOC
https://www.ijidonline.com/article/S1201-9712%2821%2900232-0/fulltext
5/n">https://www.ijidonline.com/article/S...
A phase II, randomized, controlled, open-label study
Concludes that significant improvement in clinical status on day 15 is likely due to faster viral reduction compared to SOC
https://www.ijidonline.com/article/S1201-9712%2821%2900232-0/fulltext
5/n">https://www.ijidonline.com/article/S...